Dashboard

View record

Title Efficient Process development strategies for prevalent “rare disease” drugs

File number Temp 6

Funding agency DST

Start date July 5, 2023

End Date None

Duration None

Disease category Rare disorder

Type of study Invito study

Type of data Quantitative data

Aims of objective • Process development for the cysticfibrosis drug Tezacaftor. • Process development for thelysosomal disorder drug Eliglustat (NIPER-Kolkata) • Process development of existing ASO-based Duchenne Muscular Dystrophy drug Eteplirsen to make it affordable (IACS, Kolkata; and NIPER-Kolkata).

Keyword Cystic fibrosis, Tezacaftor, Eliglustat, Lysosomal disorder, Eteplirsen, Duchenne Muscular Dystrophy, Rare disorder

Description None

Total Sanctioned budget None

Principle Investigator Prof. Ravichandiran Velayutham/None/NIPER, Kolkata

CoPrincipal Investigator Dr. Surajit Sinha/None/IACS Kolkata

CoPrincipal Investigator Dr. Vipan Parihar/None/NIPER Hajipur

CoPrincipal Investigator Dr. Vaibhav Dixit/None/NIPER Guwahati